Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule

A construction method and molecular technology, applied in the field of medicine and biology, can solve problems such as non-neutralization and denaturation

Inactive Publication Date: 2013-05-01
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recently, Waterston et al. evaluated the immunogenicity and safety of TNF-α autovaccine through a phase one clinical trial. Unfortunately, although the serum antibodies induced by the vaccine can recognize denatured human TNF-α molecules, they cannot neutralize the natural state TNF-α molecules. Human TNF-α molecule, the analysis may be due to the denaturation of the antigen during the purification process of the antigen
[0031] The above studies show that although TNF-α autovaccine is also a good way to treat diseases related to the overexpression of TNF-α, however, screening for effective T cell helper epitopes, suitable epitope insertion positions and suitable purification methods are all important factors for the treatment of TNF-α. -Critical issues in the study of α autovaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule
  • Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule
  • Building method for autovaccine by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0141] The human TNF therapeutic autovaccine prepared according to the technical scheme of the present invention is encoded with TT 830-844 (QYIKANSKFIGITEL), HEL 46-61 (NTDGSTDYGILQINSR) and PADRE (AKFVAAWT LKA) amino acid nucleic acid sequence to replace human TNF-α129 to 141 amino acid nucleic acid sequence, thereby obtaining hTNF-TT, hTNF-HEL, hTNF-PADRE fusion protein, immunized mice after purification, and compared These three molecules induce the titer of antibodies against hTNF-α and the ability to neutralize the activity of hTNF-α, and hTNF-PADRE has the best immune effect after screening. Immunization of mice with hTNF-PADRE recombinant protein can not only reduce the weight loss of mice with cachexia induced by natural TNF-α, but also prolong the survival period of mice with cachexia induced by mTNF-α; prolong the survival of mice with acute lung injury induced by LPS survival; alleviates symptoms of type II collagen-induced rheumatoid arthritis. Secondly, the rec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a building method for autovaccine in-vivo induced by aiming at human TNF(Tumor Necrosis Factor)-alpha molecule. With a step-by-step cloning method, a fusion gene of hTNF-TT830-844, hTNF-HEL46-61 and hTNF-PADRE is built; point mutation (T439-A,C440-G) is introduced into a natural human TNF gene to optimize a mRNA (Ribonucleic Acid) secondary structure; the fusion gene is cloned into a pET22b prokaryotic expression vector, and efficient expression is achieved in the bacterial strain of escherichia coli; three T accessory cell epitope peptides are introduced between the epitope peptide structure domains of hTNF by the computer-aided analysis and is fused with the hTNF-alpha to overcome the immunological tolerance of an organism for the autologous protein, and therefore the organism generates high-level humoral immune response; the generated high-level hTNF-alpha neutralizing polyclone antibody can neutralize killing activity of the hTNF-alpha on L929 cells in vitro; the hTNF-PADRE has the strongest immunogenicity; the high-level antibody can be induced under the condition of using no immunological adjuvant; and the vaccine has favorable protection and curing action on mouse models suffering from rheumatoid arthritis induced by the II-type collagen, cachexia and the like induced by LPS (lipopolysaccharide).

Description

technical field [0001] The invention belongs to the field of medical biotechnology, specifically relates to the technical fields of gene cloning, gene recombination, expression of foreign genes in prokaryotic cells, purification of target protein, etc. A method for constructing an antibody-based protein vaccine. Background technique [0002] 1. Research on TNF-α molecules and anti-TNF-α therapy [0003] 1.1 TNF-α molecule [0004] In 1975, Carswell et al. found that there was a highly active tumor cytotoxic factor in the serum of mice infected with BCG and bacterial endotoxin, which could cause hemorrhagic necrosis of tumors, but had no killing activity on normal tissue cells, and named it tumor necrosis. Factor - TNF-α. The human TNF-α gene is located on chromosome 6. The gene is 4kb long and contains 4 exons. It is linked to the MHC gene. Its precursor consists of 232 amino acids and contains a signal peptide of 76 amino acids. The mouse gene is located on chromosome 1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395C12N1/21C12N15/62C07K19/00A61P19/02A61P29/00A61P35/00
Inventor 张英起万一薛晓畅王增禄赵宁
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products